Gilman Hill Asset Management LLC Buys 1,037 Shares of GSK plc (NYSE:GSK)

Gilman Hill Asset Management LLC boosted its holdings in GSK plc (NYSE:GSKGet Rating) by 1.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,869 shares of the pharmaceutical company’s stock after buying an additional 1,037 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in GSK were worth $3,085,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Tyler Stone Wealth Management acquired a new stake in GSK in the fourth quarter valued at about $26,000. Tsfg LLC increased its holdings in GSK by 67.9% in the first quarter. Tsfg LLC now owns 618 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 250 shares in the last quarter. Glassman Wealth Services increased its holdings in GSK by 71.3% in the fourth quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company’s stock worth $28,000 after purchasing an additional 261 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in GSK in the first quarter worth approximately $30,000. Finally, Strategic Asset Management LLC increased its holdings in GSK by 119.8% in the second quarter. Strategic Asset Management LLC now owns 734 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 400 shares in the last quarter. 16.86% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft decreased their price objective on GSK from GBX 1,750 ($21.15) to GBX 1,500 ($18.12) in a report on Wednesday, September 7th. AlphaValue downgraded GSK to a “reduce” rating in a report on Tuesday, July 19th. Citigroup reaffirmed a “neutral” rating on shares of GSK in a research report on Thursday, July 21st. TheStreet cut GSK from a “b” rating to a “c+” rating in a research report on Monday, August 29th. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating in a research report on Thursday, September 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $1,700.00.

GSK Stock Down 2.4 %

Shares of GSK stock traded down $0.72 on Friday, reaching $29.29. The company’s stock had a trading volume of 177,128 shares, compared to its average volume of 6,046,734. The company has a market capitalization of $59.57 billion, a price-to-earnings ratio of 9.94, a P/E/G ratio of 1.13 and a beta of 0.61. The firm’s fifty day simple moving average is $35.90 and its two-hundred day simple moving average is $40.93. GSK plc has a 52 week low of $29.53 and a 52 week high of $46.97. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 0.83.

GSK (NYSE:GSKGet Rating) last posted its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.76 by $0.11. The business had revenue of $8.71 billion during the quarter, compared to analyst estimates of $9.35 billion. GSK had a return on equity of 27.84% and a net margin of 12.91%. Equities analysts anticipate that GSK plc will post 3.23 earnings per share for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 6th. Stockholders of record on Friday, August 19th will be paid a $0.383 dividend. This is an increase from GSK’s previous quarterly dividend of $0.35. This represents a $1.53 dividend on an annualized basis and a dividend yield of 5.23%. The ex-dividend date of this dividend is Thursday, August 18th. GSK’s dividend payout ratio (DPR) is 50.66%.

GSK Company Profile

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.